Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Stryker (SYK – Research Report) on January 24 and set a price target of $300.00. The company’s shares closed last Thursday at $255.44.
According to TipRanks.com, Antalffy is a 4-star analyst with an average return of 9.1% and a 52.0% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts.
Currently, the analyst consensus on Stryker is a Moderate Buy with an average price target of $285.00, implying an 11.5% upside from current levels. In a report issued on January 28, UBS also maintained a Buy rating on the stock with a $267.00 price target.
The company has a one-year high of $281.16 and a one-year low of $227.84. Currently, Stryker has an average volume of 1.37M.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Michigan-based Stryker Corp. was founded in 1941. The company provides medical technology products and services. It operates its business through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine.
Read More on SYK: